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Abstract
Background: The research study titled “Cluster randomised trial of the clinical and cost effectiveness of the i-gel
supraglottic airway device versus tracheal intubation in the initial airway management of out-of-hospital cardiac
arrest (AIRWAYS-2)” is a large-scale study being run in the English emergency medical (ambulance) services (EMS). It
compares two airway management strategies (tracheal intubation and the i-gel) in out-of-hospital cardiac arrest. We
describe the methods used to minimise bias and the challenges associated with the set-up, enrolment, and follow-up
that were addressed.
Methods: AIRWAYS-2 enrols adults without capacity when there is no opportunity to seek prior consent and when the
intervention must be delivered immediately. We therefore adopted a cluster randomised design where the unit of
randomisation is the individual EMS provider (paramedic). However, because paramedics could not be blinded to the
intervention, it was necessary to automatically enrol all eligible patients in the study to avoid bias. Effective
implementation required engagement with four large EMS and 95 receiving hospitals. Very high levels of data
capture were required to ensure study integrity, and this necessitated collaborative working across multiple
organisations. We sought to manage these processes by using a large and comprehensive electronic study
database, implementing efficient trial procedures and comprehensive training.
Results: Successful implementation of the study design was facilitated by the approaches used. The necessary regulatory
and ethical approvals to conduct the study were secured, and benefited from strong patient and public involvement.
Early and continued consultation with decision makers within the four participating EMS resulted in a coordinated
approach to study set-up. All receiving hospitals gave approval and agreed to collect data. A comprehensive database
and programme of training and support were implemented. More than 1500 paramedics have been recruited to the
study, and patient enrolment and follow-up has proceeded as planned.
Conclusion: Care provided by EMS needs to be based on evidence. Although participants may be experiencing
life-threatening emergencies, high-quality pre-hospital research is possible in well-designed and well-managed
studies. The approaches described here can be used to support successful research that will lead to improved
treatment and outcomes in similar patient groups.
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Background
The research study titled “Cluster randomised trial of the
clinical and cost effectiveness of the i-gel supraglottic
airway device versus tracheal intubation in the initial
airway management of out-of-hospital cardiac arrest (AIR-
WAYS-2)” is a randomised controlled trial of an inter-
vention performed by emergency medical (ambulance)
service (EMS) providers in the pre-hospital setting in
England [1, 2]. The study aims to determine whether a
new supraglottic airway device (the i-gel) is superior to
tracheal intubation when used as the first advanced airway
device in adult patients who have sustained a non-trau-
matic out-of-hospital cardiac arrest (OHCA). It is funded
by the National Institute for Health Research Health
Technology Assessment Programme (HTA reference 12/
167/102).
When a cardiac arrest occurs, the heartbeat and
breathing cease and the patient becomes unconscious
immediately [3]; this means that there is no opportunity
to obtain prior consent. In addition, the outcome from
cardiac arrest is very poor, and more than 90% of patients
do not survive to hospital discharge [4]. OHCA is sudden
and unpredictable and conducting ethical research in pa-
tients who have suffered a cardiac arrest and are imme-
diately incapacitated is challenging. Relatively small gains
in survival of 3–4% would be clinically meaningful and
worthwhile [5], providing the intervention is cost effective.
This means that large sample sizes are necessary, and
missing data could substantially undermine the validity of
study results. To improve survival following OHCA,
high-quality research is required; however, as described,
the logistical and ethical challenges of conducting research
in this patient population are challenging. The pre-hos-
pital phase of care is only part of the patient pathway in
OHCA. Hospital teams play a key role in data collection
and patient follow-up, and effective engagement with re-
ceiving hospitals is therefore necessary. Very few
pre-hospital studies are randomised controlled trials
(RCTs) [6], and some previous pre-hospital RCTs have
proved unsuccessful [7]. Appropriate study features are
therefore required to ensure that research in this patient
population is:
 Ethical, socially acceptable, and compliant with legal
and regulatory requirements
 Practicable in an emergency setting where patient
care is the priority
 Of high methodological quality, addressing the
unique challenges of this environment
 Implemented successfully to answer the study question
The AIRWAYS-2 study protocol and primary results
have been published previously [1, 2]. This paper outlines
the key methodological design features of AIRWAYS-2,
and describes how these facilitated successful implementa-
tion of the study in receiving hospitals to address the
requirements outlined above. Pre-hospital issues will be
described in a separate publication. Our study design
choices and experiences may inform future similar studies
in patients suddenly incapacitated by life-threatening
emergencies, to enhance research quality and success, and
improve long-term outcomes for patients.
Methods: study design
Cluster randomisation and automatic enrolment
In AIRWAYS-2, the potential participants are uncon-
scious, in need of immediate emergency care, and clinical
necessity is therefore the overriding priority. For this
reason, it was not possible to design the study to rando-
mise individual patients, and a cluster randomised design
was deemed most appropriate. We chose to randomise
the EMS provider (paramedic), treating each participating
paramedic as a cluster. This choice meant the study had a
large number of clusters, with average cluster size being
relatively small (the median number of OHCAs attended
by a paramedic annually was three in our previous feasi-
bility study [8]), which minimises the loss of efficiency due
to observations within clusters not being independent.
Paramedics were randomised in a 1:1 ratio using a
purpose-designed, secure internet-based system. This
ensured that the number of paramedics in each group
was equal; however, some imbalance in the number of
patients enrolled was possible as a result of chance.
Since it was not possible to blind the participating para-
medics to the study intervention, it was necessary to
ensure that all eligible patients were enrolled in order to
avoid bias. We therefore adopted a model whereby every
eligible patient attended by a participating paramedic
was automatically enrolled into the study. In this way,
the participating paramedics could not influence whether
a patient was enrolled, while EMS control room staff, who
allocate paramedics to individual patient calls, were
blinded to both paramedic participation and allocation.
Where two participating paramedics were allocated to the
same patient call, the first paramedic ‘at the patient’s side’
was assigned; if both paramedics arrived together, the
attendant paramedic, rather than the driver was included
for study purposes. Patients could either be consciously
enrolled by the participating paramedic, or automatically
enrolled following identification of their eligibility subse-
quent to the OHCA. Data for OHCA are routinely
collected and reported by ambulance services [9] and
interrogation of these, in addition to the study-specific
data collection, meant that all (i.e. as close to all as it is
possible to be sure of) eligible participants were included;
we do not anticipate that there was a significant level of
‘missingness’ in the data.
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Data collection, patient information and consent
Research in OHCA is challenging because it requires the
recruitment of incapacitated adults without the oppor-
tunity to obtain prior informed consent. Furthermore,
because AIRWAYS-2 is a trial of advanced airway
management in the very early stages of OHCA, the
intervention is completed within a very short time from
the onset of the cardiac arrest and before consent can be
sought. For this reason, we had to demonstrate that
strict ethical safeguards and robust patient and public
involvement were in place when we designed the study
and that there was collective equipoise between the two
study treatments.
The following features addressed these challenges:
 We decided to use a model of deferred consent for
survivors, and a waiver of consent for those who did
not survive to hospital discharge. We therefore
needed to obtain approval from the Confidentiality
Advisory Group (CAG) in England to be able to retain
data on our primary outcome (modified Rankin Scale
score at hospital discharge or 30 days post-OHCA,
which assigns a score of 6 to non-survivors) for all
participants enrolled in the study.
 We considered a model of approaching relatives to
seek their agreement to retain the data collected
from patients who did not survive; however, there is
no basis for this option in English law. There is also a
risk that it could generate differential consent rates for
patients who did and did not survive, undermining
the internal validity of the study, which requires
complete or near-complete primary outcome data on
all patients enrolled. Furthermore, we are aware that
informing relatives that their recently deceased loved
one was involved in a research study has a high risk of
increasing distress and uncertainty without benefit
[10–12]. Therefore, after careful consideration, and
with the agreement of our patient public involvement
(PPI) group, we decided not to inform the relatives of
enrolled patients who did not survive the initial
cardiac arrest that they had participated in a research
study. This approach was possible because both airway
interventions are currently in use in English EMS, and
so OHCA patients could have received one inter-
vention or the other during routine patient care
outside the study.
 For participants who survived to hospital discharge,
we sought retrospective consent to collect follow-up
data at 3 and 6months. Our PPI group recommended
that patients be informed of the study and asked to
consent at the time that they were discharged from
the intensive care or coronary care unit, but before
hospital discharge. Seeking consent at this time
required hospital-based research nurses to carefully
monitor the status and location of patients recovering
from OHCA, which was time consuming and also led
to some patients being discharged from hospital before
they could be approached. Therefore, to ensure all par-
ticipants could be informed about the study, we also
obtained approval to request written consent via post.
To maximise consent rates, participants were given
three consent options:
1) Active follow-up. Data were collected from their
medical records and they were invited to complete
questionnaires about their ongoing health and
wellbeing at 3 and 6months after OHCA.
2) Passive follow-up. Data were collected from the
patient’s medical records, but they were not
contacted again, nor invited to complete follow-up
questionnaires.
3) No further involvement. No further information
was collected, but stating clearly that the
information already collected would be retained and
included in the data analysis. Anonymity of the
participant was assured.
A proportion of participants who experience an
OHCA remain incapacitated, and so the study was
designed so that a personal consultee (usually a close
relative) could provide an opinion as to the follow-up
option that would likely be preferred by the patient.
Securing regulatory approvals
At the time of set-up, the approval process for research
involving patients at hospitals in the UK involved each
hospital completing a site-specific information (SSI)
form, detailing the research activities performed at that
site [13]. Hospitals were then required to provide local
research governance permissions, which included signing
a contract [14].
We recognised that obtaining approval from each
hospital would be time consuming, and a streamlined
approach was required. Table 1 provides details of the
process. The key objective was to reduce the burden of
obtaining approvals.
The lead Clinical Research Network (CRN) offered
extensive support during the study set-up phase and
agreed that a generic SSI form could be used to gain
hospital approvals. This meant that all hospitals could
be provided with the pre-populated generic SSI form,
reducing the administrative burden. Obtaining contract
signatures was identified as an aspect of the approval
process that had the potential to cause significant delays
[13]. To mitigate this, we provided sites with a ‘State-
ment of Responsibilities’ document in place of the usual
contract [14], which detailed the support that each
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hospital would receive in respect of their participation.
This document did not require individual site sign-off.
As part of the approval process, it is usual for hospitals
to format study information and consent forms on their
own headed paper. Given that the study interventions
were delivered in the pre-hospital phase of care and the
in-hospital activities related to follow-up data collection,
this was not necessary and standard documents could be
provided, further reducing administration locally.
Methods: study implementation
Identification and engagement of key stakeholders
All enrolled patients transferred to the emergency depart-
ment required follow-up data to be collected in hospital.
Hospitals identified as potential receiving sites were any of
those within, or bordering the geographical area served
by, the four participating EMS. It was not possible to
predict or influence which hospital an enrolled patient
would be taken to, and this meant that all 95 hospitals
served by the four ambulance services needed to partici-
pate in the trial. If a hospital refused to take part or could
not provide the necessary approval, we could not collect
data for enrolled patients taken to that hospital.
To facilitate engagement from all hospitals it was agreed
that a multi-faceted approach would be required. We
planned to identify key stakeholders who could promote
awareness of the study and facilitate communication. Early
engagement and good communication with hospitals was
essential, as was a clear outline of what their participation
would involve. The design of the study, with the interven-
tion administered solely during the pre-hospital phase of
care and hospital research activities being limited to
obtaining informed consent and data collection meant
that Principal Investigators (PIs) were not required at hos-
pital sites; rather a non-medical local collaborator (LC)
could be identified as the main point of contact. In the
UK, the usual approach is for hospitals to be invited to
express an interest in taking part in a research study, and
for decisions regarding participation to be made ac-
cording to local processes [15]. A different approach
was required to ensure that all hospitals that might
receive an AIRWAYS-2 patient took part. In our com-
munications, we provided concise study information
and a clear rationale for including all receiving hospi-
tals, rather than inviting hospitals to express an interest
in participating.
Training and management of research staff at a large
number of hospitals
Another major challenge was training the staff at the
receiving hospitals. We needed to train over 300 staff at
95 hospitals. When setting up a study it is imperative to
ensure the research staff have the appropriate qualifica-
tions and training and understand the study protocol.
Training is often delivered in the form of face-to-face
trial initiation visits at each of the research sites. This
can significantly increase the set-up costs and delay
opening a site. To mitigate this, we decided to train the
hospital staff using online training videos and a detailed,
online study manual; this would enable staff to revisit the
material as often as they wished and would also make it
easier for new staff to join the hospital study teams.
Design and delivery of a comprehensive electronic study
database
We also invested resources in developing an in-house,
bespoke electronic management system that would help
manage hospital-specific documentation and facilitate
access to central study documents. Figure 1 shows the
different components of the electronic management and
training system.
In designing the electronic management system there
were several objectives in mind. The system had to func-
tion as the primary communication tool between the
study team and the hospital staff, facilitate online
Table 1 Streamlining the hospital approval process
Normal process AIRWAYS-2 Rationale for streamlining Advantage for hospital
Site-specific assessment
form for each hospital
Generic site-specific
form for all hospitals
No need for hospital to complete
information about local site activities
Patient consent and
information forms on
local hospital trust
headed paper
Patient consent and
information forms on
sponsor/trust headed paper
Patient recruitment being
carried out by ambulance services.
No change of practice in hospital
and activity limited to follow-up
No need for hospital to spend time
localising patient documents, as
documents provided to hospital by
study team on ambulance trust/sponsor
headed paper
Principal Investigator Local collaborator No serious adverse events
expected to occur in hospital;
likely to occur at roadside and would
be reported by ambulance trust
A research nurse, rather than a doctor,
could act as the hospital’s main point
of contact for the study
Third-party contract
requiring sign-off at
each hospital
Simple one-page document
‘statement of responsibilities’
issued to hospital sites; no
signature required
Hospital not responsible for
participant enrolment or delivering
intervention so a simpler
agreement is sufficient
No complicated legal terminology for
contracts department to review.
No signature, therefore less administration
for research and development teams
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training, provide a document library, be easy to use, and
reduce the carbon footprint of the trial.
The system enabled users (principally research staff
responsible for data collection in the pre-hospital and
in-hospital phases of care) to register for a study account
online, complete an electronic delegation log, and upload
relevant information and certificates. It was designed to
allow users to select their delegated tasks (as appropriate
to their role within the study and differing for pre-hospital
and in-hospital staff ) and for approval for access to be
granted by the study manager once the tasks and docu-
mentation checks were verified as accurate and complete.
All sites had access to the trial master file that was main-
tained by the study team and a local site file that enabled
sites to upload site-specific documents.
The trial management system automatically generated a
unique study identifier and produced patient-specific docu-
ment packs once a minimum dataset had been uploaded by
the research paramedics. Depending on the consent option
selected by the patient or their consultee, the trial system
created a set of electronic case report forms (eCRF; a copy
of the eCRF is available in Additional file 1) to enable the
correct data to be collected for each individual patient. This
helped to reduce the workload for the sites, as contact
information (for patients and regional research teams) was
automatically pre-filled and the correct forms printed. The
database had inbuilt and complex data verification and
enabled data queries to be sent to research paramedics on a
weekly basis.
Results
We obtained study-wide research ethics committee
approval in September 2014, with support for automatic
enrolment of eligible patients. Our PPI group provided
valuable advice which guided various aspects of the study
design; we described their input in our applications to
demonstrate their role in addressing the major ethical
challenges. At the same time, we obtained approval
from the CAG to collect primary outcome data without
prior consent.
Four EMS agreed to collaborate in the study. Involving
key stakeholders from the ambulance services at an early
stage of the planning process enabled the identification
of potential issues so that differences between services
could be addressed. At two investigator meetings held
during set-up, study-wide decisions on clinical practice,
logistical issues, and study management were made. We
agreed a common communications strategy that ad-
dressed paramedics’ concerns, and enabled the wider com-
munity (potential patients, EMS providers who were not
participating, and healthcare providers) to be informed
about the study. We commenced the approval process for
the four EMS on 27 January 2015 and the NHS permis-
sions were in place by 5 March 2015.
We mapped the local National Institute for Health
Research Clinical Research Networks (NIHR CRNs) [16]
(Fig. 2) covering the study sites, based on the destination
hospital to which an AIRWAYS-2 patient might be taken.
The lead CRN publicised the trial in their e-newsletter
for the research community, and facilitated discussions
with the critical care specialty research leads in the rele-
vant CRN regions. This enabled the specialty leads to be
approached for help in setting up the study in their local
hospitals. A teleconference to further engage with the
speciality leads was held and proved fruitful; they
provided insights regarding variations in processes
across the different hospital sites, gave valuable advice
on how to utilise resources in each of their regions,
agreed to promote the study at local meetings, and
helped to identify suitable contacts within each hospital.
Fig. 1 Electronic trial management system. CV Curriculum Vitae, GCP Good Clinical Practice, GP general practitioner, SAE severe adverse event
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Six of the 11 invited specialty leads and representatives
from three of the four main CRN regions that covered the
ambulance services took part in the teleconference. The
representatives from the three CRNs were able to high-
light any potential issues with study support in terms of
lack of dedicated research nurses at individual sites. This
enabled us to plan effectively and we identified hospitals
that would potentially need the study regional research
nurses to assist with data collection.
We used the CRN mapping (previously described) to
identify LCs during the planning phase. By identifying LCs
early on, the hospital teams had time to discuss how the
study would be implemented locally, and were able to
nominate clinical staff in both emergency and critical care
departments who would assist in tracking patients and
collecting the required data. With the support of the critical
care speciality research leads and the local CRNs, 61 of the
95 LCs were identified before hospital sites were invited to
take part in the study. Most of the hospitals accepted that
the role of LC could be undertaken by non-medic staff
(research nurses in the majority of cases). Four hospitals
requested that a doctor undertake this role, and in these
sites an intensive care consultant was identified. The iden-
tification of LCs before opening the study facilitated
internal discussions, raised awareness of AIRWAYS-2,
and paved the way for the opening of the study.
Fig. 2 Clinical Research Network (CRN) involvement in the AIRWAYS-2 trial
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Obtaining NHS approvals was facilitated by the
approaches used. We formally initiated the approval
process for hospitals on 14 April 2015, and received the
first approval 6 days later. Ninety-two of the 95 hospitals
accepted the ‘Statement of Responsibilities’, with only
three sites requesting a formal contract. We went on to
receive NHS management permission from all 95 hospi-
tals identified as potential receiving sites, with the last site
agreeing to participate on 4 November 2015.
Communications with hospital staff commenced 6
months before the planned start of patient enrolment.
Figure 3 shows the timeline for communication.
The use of an electronic management system greatly
enhanced the efficiency of the study; staff were able to ac-
cess the electronic resources in their own time which
meant that face-to-face site initiation visits were unneces-
sary and that the study manager was able to conduct these
by telephone. In addition, the study team were able to
monitor training records and site files without visiting the
local hospital. The resources required to manage study
amendments were reduced significantly; new study docu-
ments could be uploaded to the trial master file and all
sites were then able to access these immediately.
Hospital research staff were initially uncertain about
online training and electronic site files, but after receiving
the training manual and using the electronic management
system, the feedback reported to the regional research
nurses was extremely positive. One of the most important
benefits of the electronic management system was its role
as an efficient primary communication tool. On enrol-
ment of an eligible patient, a minimum dataset was
entered manually by the research paramedic (these data
were not linked to hospital clinical records or other
routine data sources); the system then allowed the central
research team to notify hospital staff via email that an
AIRWAYS-2 patient had entered their hospital, and
enabled staff to track the patient through their hospital
pathway, approach the patient for deferred consent at the
correct time, and enter their data directly onto the data-
base. In some auto-enrolment cases, some months had
elapsed between the OHCA and data entry and this meant
that the patient was no longer in hospital; these patients
were sent a postal invitation by the hospital staff.
Patient recruitment to the AIRWAYS-2 study com-
menced on 1 June 2015. More than 1520 paramedics were
recruited, randomised, and trained across the four colla-
borating EMS. Patient recruitment was open for just over
2 years and closed on 13 August 2017. The primary
clinical results have been reported previously [2].
The key lessons learnt from the design and implemen-
tation of this study are summarised in Table 2.
Discussion
AIRWAYS-2 is a large and complex study that aims to
guide future initial airway management by EMS providers
(paramedics) in patients experiencing out-of-hospital
cardiac arrest. All patients enrolled in the trial lacked the
capacity to consent, and the time-critical nature of the
condition meant that there was no opportunity to identify
or approach a consultee. Research in the emergency
setting is challenging but essential if we are to improve
future clinical practice [17]. The design of AIRWAYS-2
needed to be acceptable to patients, their family and
carers, with due consideration of the many ethical issues
that the study raised. We were guided by our patient and
public group in this regard.
Blinding of individual paramedics was clearly not
possible; this presented another challenge because it
required that all patients attended by participating para-
medics were included. The only way to achieve this was
enrol eligible patients automatically. To enable this, we
needed to gain approval for the collection and retention of
a minimal dataset without consent. Legal provisions enable
research in an emergency setting providing all proposed ac-
tivities have approval from an appropriate research ethics
committee [18]. The ethics committee demonstrated a high
degree of understanding of the nature of prehospital re-
search; recent increases in research activity by EMS and
previous work completed by our team are likely to have
been beneficial in this regard [7].
The set-up of AIRWAYS-2 was a large undertaking,
and we identified a widespread lack of familiarity with
Fig. 3 Timeline for hospital communications. Early correspondence with hospitals took the form of a trial introduction letter which answered the
question “Why do Acute Trusts need to know about this trial”. Follow-up correspondence was sent 2 months later; this provided a trial design
summary and information about the incentives the hospital would receive if they admitted an AIRWAYS-2 participant. Further correspondence was
sent 1 month later; this provided targeted information answering common questions received from the hospitals. SSI site-specific information
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the unique features and complexity of pre-hospital re-
search. Many hospitals had no experience of participating
in EMS-led studies, or of approaching patients for consent
who had been enrolled in a study outside of hospital.
There was a lack of understanding that the automatic
enrolment of patients by participating EMS providers
meant that hospitals might receive a recruited patient at
any point following activation of the ambulance service
site, and that the patient was already enrolled in the study
under a waiver of consent. Consequently, it was not
possible for us to take a staggered approach to set-up. We
recognised the potential risks that delays in obtaining
approvals would pose to the successful implementation of
the study [13, 19] and we adopted a proactive approach to
managing these. Early and effective engagement and
communication with hospital clinical and research
management staff, regional clinical leads, and research
network colleagues were key factors in this. In regions
where we were unable to engage with the CRN re-
presentative or specialty leads it was necessary to
follow-up with hospital teams individually, and the
workload and the time taken to engage with the appro-
priate teams was increased in these cases.
One of the greatest risks to the study was the require-
ment for all hospitals to agree to follow-up participants,
and we recognised that it would be difficult to achieve
approval from all hospitals that might receive an enrolled
patient [20–22]. At the time of set-up, hospitals were
assessed on various performance metrics as part of the
national research governance process; one of these metrics
was the time taken to review and provide approval for
studies. In 16 of the 95 hospitals, it was not possible to
identify an LC before the start of patient recruitment. In
these sites, the hospital risked a metric target not being
met, and seven hospitals initially abandoned the study as a
result. We adopted a flexible approach, making allowances
for the differing models, challenges, and staff shortages
within individual organisations in order to engage all
hospitals successfully. When a dedicated research nurse
was not available in an individual hospital, we agreed that
the AIRWAYS-2 regional research nurses would complete
follow-up for admitted patients. The majority of hospitals
had agreed to support the study in time for patient
recruitment to commence. In sites where we had not
received approval within 5 months, the sponsor escalated
the issue to senior directors within the hospitals to remind
them that they had a duty to support research. Where
sites had not issued permission but had received an
eligible patient, we worked closely with regional CRNs to
expedite approvals in order that consent to follow-up
could be requested. Eventually all 95 sites agreed to
support the study.
We made early contact with the NIHR CRNs for the
regions covered by the collaborating ambulance services
and utilised the support they provided to good effect [17].
The assistance provided by the CRNs when communica-
ting with hospitals in their area was helpful, and
intelligence regarding local resources and capacity was
used in planning. We found some inconsistency in terms
of CRN support for AIRWAYS-2, and this had a direct
bearing on the time taken to secure local approvals. In the
three regions where good support was in place we expe-
rienced minimal resistance to setting up the study,
whereas in the one region where the local CRN was not
fully supportive the timelines for approval were extended,
and more time and effort was needed to gain agreement
from the hospitals.
The electronic system was crucial when managing sites.
In most trials with many hospitals taking part, a staggered
approach to site start-up is used. In AIRWAYS-2 this was
not possible since once patient enrolment began in an
ambulance service, there was no way to predict which
hospitals served by that ambulance service would receive
a patient; approvals and training of staff at all 95 hospitals
needed to be completed before patient enrolment com-
menced. Had this not been possible, there was a risk that
participants would not be informed about the trial in a
Table 2 Key lessons from the AIRWAYS-2 trial
• When the randomisation of individual patients is not possible, a cluster
randomised design may be considered. A large number of small clusters
will reduce intra-class correlation.
• Automatic enrolment of all eligible patients minimises the risk of bias
in circumstances where those responsible for participant enrolment are
not blinded to treatment allocation.
• For research in emergency situations it may be necessary to establish
ways of collecting outcome data that do not rely on patient consent. In
England, approval from the Confidentiality Advisory Group (CAG) can
facilitate this.
• Strong patient and public involvement (PPI) in study design helps to
address challenging ethical and patient consent issues.
• Hospital teams may not be used to collaborate in emergency medical
(ambulance) services-led research.
• Once an emergency medical (ambulance) service begins patient
recruitment, any of the hospitals in the area covered by that service
could potentially receive a patient. Therefore, a phased approach to
opening hospital sites is not possible and alternative approaches are
required.
• Early identification of key stakeholders at participating healthcare
organisations, and the provision of concise study documents, facilitates
effective engagement and raises awareness of the study.
• A study-wide communications strategy, approved by an ethics com-
mittee, enables local communities and healthcare organisations to be
informed about the study, and minimises the risk of unwilling patients
being enrolled.
• An electronic system can support effective and efficient study
management; it facilitates online training for site staff, provides an up-
to-date document repository, and enables printing of patient-specific
document packs.
• For patients recruited to clinical trials in emergency situations a flexible
approach to follow-up will maximise participation.
Robinson et al. Trials          (2019) 20:108 Page 8 of 10
timely manner, and the opportunity to approach them and
obtain consent for continued study involvement and data
collection from those patients that survived to hospital
discharge would be lost. The electronic study manage-
ment and online training systems significantly reduced the
time and resources required to deliver training to staff,
and enabled the trial to operate virtually paper free
throughout.
Conclusion
EMS are increasingly research active. Incidents attended
by EMS providers (paramedics) can be life-threatening
emergencies, and this adds complexity to the design and
implementation of research in this setting. Early and
comprehensive engagement with key stakeholders is
essential in the set-up of collaborative trials. Strategies
to identify risks and practical problems before a study
opens to recruitment can effectively mitigate against
these, and a study-wide communication strategy can be
utilised effectively.
The AIRWAYS-2 trial describes a methodological
approach to successful and ethical research in the most
severely ill and injured patients who lack capacity and
require immediate life-saving treatment. The key fea-
tures of study design and implementation described here
can be used to support deliverable research that will lead
to improved treatment and outcomes in this and similar
patient groups.
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